Stryker (SYK) announced that it has completed the acquisition of Inari Medical (NARI), a company that provides innovative solutions for venous thromboembolism, or VTE, clot removal without the use of thrombolytic drugs. The addition of Inari brings an established peripheral vascular position to Stryker in the fast-growing VTE segment. Inari’s product portfolio is highly complementary to Stryker’s Neurovascular business and includes two novel mechanical thrombectomy solutions-the FlowTriever System for the treatment of pulmonary embolism and the ClotTriever System for thrombectomy in the peripheral vessels-as well as emerging therapies.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- Kadant to replace Inari Medical in S&P 600 at open on 2/19
- Stryker price target raised to $443 from $418 at Barclays
- Stryker price target raised to $450 from $410 at Argus
- Stryker price target raised to $413 from $409 at Truist
- Alphatec likely to benefit as Stryker exits spinal implants, says Lake Street